TRT & Prostate Cancer: Separating Fear from Evidence

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

Modern research refutes the long-held belief that TRT fuels prostate cancer, showing no increased risk of incidence or recurrence. The 'saturation kinetics' model explains why restoring physiological testosterone levels is generally safe for the prostate.

TRT and Prostate Cancer: Separating Fear from Evidence

For decades, the relationship between Testosterone Replacement Therapy (TRT) and prostate cancer has been a source of significant apprehension for both patients and clinicians. The prevailing dogma, based on a single 1941 study by Huggins and Hodges, suggested that testosterone fueled prostate cancer growth. However, a wealth of modern research has largely debunked this fear, providing a more nuanced and reassuring understanding.

The historical concern stemmed from the observation that androgen deprivation therapy (ADT), which drastically lowers testosterone, is an effective treatment for advanced prostate cancer. This led to the logical, but ultimately flawed, assumption that increasing testosterone via TRT would necessarily stimulate prostate cancer. This "testosterone-cancer hypothesis" dominated urological practice for over 70 years.

Modern research, however, paints a different picture. Numerous observational studies and meta-analyses have consistently failed to demonstrate an increased risk of prostate cancer incidence or recurrence in men receiving TRT. For example, a comprehensive review by Michaud et al. (2015) concluded that most studies suggest no relationship between testosterone supplementation and prostate cancer incidence and progression.

The concept of "saturation kinetics" helps explain this apparent paradox. Prostate cancer cells, like normal prostate cells, have a finite number of androgen receptors. Once these receptors are saturated with a certain level of testosterone (typically around 250-300 ng/dL), further increases in testosterone do not lead to additional stimulation of prostate cancer growth. This is analogous to a sponge: once it's saturated with water, adding more water doesn't make it absorb more.

Furthermore, evidence suggests that low testosterone itself may be a risk factor for more aggressive prostate cancer. Some studies indicate that men with very low testosterone levels may have a higher chance of being diagnosed with higher-grade prostate cancer (Morgan et al., 2018). This challenges the old paradigm and suggests that restoring physiological testosterone levels might even be protective or at least neutral.

Unlike the historical fear, which was based on limited data and extrapolated conclusions, current evidence is derived from larger, more robust studies. These studies often include long-term follow-up and careful monitoring of prostate-specific antigen (PSA) levels and prostate health. This allows for a more accurate assessment of risk and benefit.

The safety of TRT in men with a history of prostate cancer, particularly those who have undergone definitive treatment like radical prostatectomy or radiation, has also been extensively studied. The current literature suggests that TRT can be safely administered to carefully selected men after definitive treatment for localized prostate cancer, with no increased risk of biochemical recurrence (Gibson et al., 2025).

In clinical practice, we now approach TRT in men with hypogonadism and prostate cancer concerns with a much more evidence-based perspective. A 70-year-old patient who had a radical prostatectomy 5 years ago for low-grade prostate cancer, now with undetectable PSA and symptomatic hypogonadism, can often safely initiate TRT under close monitoring. We've seen these patients experience significant improvements in quality of life without any adverse impact on their prostate cancer surveillance.

The practical takeaway is that the long-held fear linking TRT directly to prostate cancer growth is largely unfounded by modern scientific evidence. While careful screening and monitoring, including regular PSA checks, are still essential for all men on TRT, especially those with risk factors or a history of prostate cancer, the current consensus is that TRT does not increase the risk of prostate cancer incidence or recurrence. Discuss your individual risk factors and prostate health history with your physician to make an informed decision about TRT.